Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$285,370 Mln
P/E Ratio
16.91
P/B Ratio
11.82
Industry P/E
--
Debt to Equity
0.72
ROE
0.81 %
ROCE
53.17 %
Div. Yield
2.77 %
Book Value
32.17
EPS
22.64
CFO
Kr.545,605.00 Mln
EBITDA
Kr.626,068.00 Mln
Net Profit
Kr.444,078.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S - ADR
| -28.74 | -20.24 | -23.92 | -51.06 | 3.46 | 13.67 | 8.08 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Novo Nordisk A/S - ADR
| -16.72 | 52.87 | 20.84 | 63.51 | 23.32 | 28.67 | -12.48 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and... internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880 Read more
President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Headquarters
Bagsvaerd
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Novo Nordisk A/S - ADR stood at $ 465,795 Mln as on 31-Dec-24
The share price of Novo Nordisk A/S - ADR is $61.30 (NYSE) as of 23-Apr-2025 16:27 EDT. Novo Nordisk A/S - ADR has given a return of 3.46% in the last 3 years.
Novo Nordisk A/S - ADR has a market capitalisation of $ 285,370 Mln as on 22-Apr-2025. As per Value Research classification, it is a company.
The P/E ratio of Novo Nordisk A/S - ADR is 16.91 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Novo Nordisk A/S - ADR and enter the required number of quantities and click on buy to purchase the shares of Novo Nordisk A/S - ADR.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
The CEO & director of Mr. Lars Fruergaard Jorgensen. is Novo Nordisk A/S - ADR, and CFO & Sr. VP is Mr. Lars Fruergaard Jorgensen.
There is no promoter pledging in Novo Nordisk A/S - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Novo Nordisk A/S - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
80.78
|
|
Operating margin(%)
|
44.36
|
|
Net Margin(%)
|
34.78
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Novo Nordisk A/S - ADR was $100,988 Mln.
$1.39
(
